True North Therapeutics closes $45mm Series D

15:40 EDT 18 Oct 2016 | Elsevier Business Intelligence

True North Therapeutics Inc. (creating rare disease therapies that inhibit the complement pathway) raised $45mm in its oversubscribed Series D financing led by first-time backers HBM Partners and Redmile Group and returning shareholder Perceptive Advisors. Other existing investors and new buyer Franklin Templeton Investments also participated. The company will use the funds for ongoing development of its lead compound TNT009, which is in Phase Ia/IIfor cold agglutinin disease, warm autoimmune anemia, antibody-mediated rejection, and bullous pemphigoid.

Original Article: True North Therapeutics closes $45mm Series D


More From BioPortfolio on "True North Therapeutics closes $45mm Series D"

Quick Search

Relevant Topics

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...